Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Lewis Katz School of Medicine at Temple University, Fox Chase Cancer Center Researcher Lucia Borriello Elected to Board of Directors of the Metastasis Research Society
PHILADELPHIA (June 11, 2024) — Lucia Borriello, PhD, Assistant Professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University and a member of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently elected to the Board of Directors for the Metastasis Research Society (MRS).
The MRS was founded in 1984 and is the preeminent international professional society supporting progressive research on important processes that will help improve the understanding and treatment of cancer metastasis, the spread of cancer from its original site to other parts of the body. The MRS facilitates the exchange of information among researchers, clinicians, patients, and advocates. It additionally seeks to educate the public about metastatic cancer and raise awareness about insufficient funding for such research worldwide.
“It is a great privilege to be elected to the Board of Directors for the Metastasis Research Society,” said Borriello. “The MRS has played a significant role in my career and has provided me with invaluable opportunities to connect with colleagues and friends. It is a very welcoming society, highly supportive of colleagues and junior investigators. It will be my pleasure to give back to our community. I am looking forward to working with the MRS and advancing metastasis research with the goal of improving the lives of patients.”
Borriello will assume her role at the upcoming 20th Biennial Congress of the MRS, which is being held in London June 23-25. She will serve an initial term of four years.
Borriello earned her doctoral degree from the University of Paris. She completed postdoctoral work in hematology and oncology at the Children’s Hospital of Los Angeles and the University of Southern California, and in anatomy and structural biology at the Albert Einstein College of Medicine in Bronx, New York.
Borriello’s Temple lab, which opened in 2022, focuses on understanding the biology of dormant tumor cells. Her research investigates how the tumor microenvironment, which consists of normal cells in the immediate vicinity of cancer cells, regulates the mechanisms of dormancy and awakening of tumor cells. The aim of this research is to identify new therapies to target dormant tumor cells and prevent or stop the progression of metastatic disease.
Her research interests include breast cancer, lung cancer, cancer signaling, dormancy, metastasis, the tumor and immune microenvironment, and therapeutic resistance. She is a member of the American Association for Cancer Research, the American Society for Cell Biology, the American Association of Immunologists, the Association for Women in Science, and the European Association for Cancer Research.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427